SCHEMBL22724482

SCHEMBL22724482

CCOc1ccc2cc(-c3ccc(OC)cc3)c(=O)n(-c3ccc(Cl)cc3)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 10/20 0.49
CYP1A2 P05177 9/20 0.49
ALDH1A1 P00352 8/20 0.49
CASP1 P29466 7/20 0.49
CASP7 P55210 7/20 0.49
HIF1A Q16665 5/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
HSD17B10 Q99714 4/20 0.49
CYP2D6 P10635 2/20 0.49
GLA P06280 2/20 0.49
CYP3A4 P08684 6/20 0.49
MAT2A P31153 5/20 0.45
TSHR P16473 6/20 0.44
LMNA P02545 4/20 0.44
HTT P42858 2/20 0.44
XBP1 P17861 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CYP2C19 P33261 2/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22724307 0.87 MAT2A (0.59) CYP2D6MAT2ACYP2C19CYP2C9
SCHEMBL22724254 0.87 MAT2A (0.44) USP2CYP1A2ALDH1A1CASP1CASP7
SCHEMBL29837907 0.87 MAT2A (0.59) CYP2D6MAT2ACYP2C19CYP2C9
SCHEMBL22724295 0.87 MAT2A (0.44) USP2CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22724344 0.86 MAT2A (0.43) USP2CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22719012 0.86 MAT2A (0.45) USP2CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22724200 0.84 MAT2A (0.46) USP2CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22724480 0.84 MAT2A (0.53) CYP2D6MAT2ACYP2C19CYP2C9
SCHEMBL22724264 0.84 MAT2A (0.45) USP2CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22724509 0.83 ALDH1A1 (0.44) USP2CYP1A2ALDH1A1CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020243376-A1 HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER AGIOS PHARMACEUTICALS, INC. (US) 2020-12-03 WO disclosed